Hypereosinophilic Syndrome (HES) Study for Children
Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 years with Hypereosinophilic Syndrome
SEX AT BIRTH: All
HEALTHY PARTICIPANTS: No
LOCATION: University Hospitals Rainbow Babies & Children’s
Learn More About This Research Study
For more information, please contact study coordinator, Erica Denallo at 216-286-7453 and leave a message or click the link to the study survey below.
Study Purpose
The purpose of this study is to learn more about Hypereosinophilic syndrome (HES) and to test the efficacy and safety of an investigational drug, mepolizumab on children (aged 6 to 11 years) and teenagers (aged 12 to 17 years) who have and are being treated for HES. This medication is already FDA- approved for children and adults ages 12 and up with HES.
Who Can Participate
Participants between the ages of 6 and 17 years of age diagnosed with Hypereosinophilic Syndrome may be eligible for this study.